The global Neuroendocrine Tumor (NET) Treatment Market size is expected to reach USD 3.33 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to register a CGAR of 10.4% during the forecast period. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.
For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.
Request a Sample Copy of the Global Neuroendocrine Tumor Treatment Research Report @ https://www.grandviewresearch.com/industry-analysis/neuroendocrine-tumor-net-treatment-market/request/rs1
Further key findings from the study suggest:
Have Any Query? Ask Our Experts@ https://www.grandviewresearch.com/inquiry/5490/ibb
Grand View Research has segmented the global neuroendocrine tumor treatment market on the basis of product, site, end use, and region:
NET Treatment Product Outlook (Revenue, USD Million, 2014 – 2025)
NET Treatment Site Outlook (Revenue, USD Million, 2014 – 2025)
NET Treatment End-use Outlook (Revenue, USD Million, 2014 – 2025)
NET Treatment Regional Outlook (Revenue, USD Million, 2014 – 2025)
Browse Related Category @
Migraine Drugs Market: Increased uptake of novel drug classes, launch of Calcitonin gene-related peptide (CGRP)-based therapies, and high unmet needs are some of the key factors driving market growth.
Central Nervous System (CNS) Therapeutic Market: Advancements in diagnostics, therapeutics, and drug discovery techniques are primarily driving the growth of the market.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:201, Spear Street, 1100 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/neuroendocrine-tumor-net-treatment-market